logo

FDA Calendar

Share
Company Name Alnylam Pharmaceuticals Inc.
Drug Name Patisiran (NDA)
Event Name FDA decision on Patisiran for the treatment of hereditary ATTR (hATTR) amyloidosis
Event Date 08/11/2018
Outcome Date 08/10/2018
Outcome FDA approved ONPATTRO (patisiran) on August 10
Drug Status Priority review
Rival Drugs
Market Potential
Other Approvals
News
Return to FDA Calendar